Skip to content

Author

Simona Sica

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

ALLOGENEIC TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA IN THE ERA OF NOVEL THERAPIES: CHANGING INDICATIONS AND DYNAMIC RISK ASSESSMENT

Allogeneic HSCT remains a major potentially curative treatment for patients with AML at high risk of relapse. However, the rapid development of targeted agents and novel non-intensive therapies has substantially changed the therapeutic landscape, raising questions regarding the optimal timing and indications for transp...

Simona Sica, F. Frioni, M. Breccia et al. · 0 citations
Review Open access Oct 2026

MOLECULAR MARKERS IN AML: PROGNOSTC IMPLICATIONS AND IMPACT ON TREATMENT DECISION-MAKING

Acute myeloid leukemia (AML) is a biologically heterogeneous hematologic malignancy in which recurrent cytogenetic and molecular abnormalities critically influence diagnostic classification, prognosis, therapeutic allocation, measurable residual disease (MRD) assessment, and relapse biology. Over the last decade, next-...

P. Chiusolo, R. Maggi, Angela Alessi et al. · 0 citations
Oct 2026

Rationale and Design of the CARdio-Tox Study: A Prospective Evaluation of Cardiovascular Toxicity in Patients Receiving Chimeric Antigen Receptor-T (CAR-T) Cell Therapy.

Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as an innovative treatment of haematologic malignancies; however, its use is frequently complicated by Cytokine Release Syndrome (CRS), an increasingly recognized driver of cancer therapy-related cardiovascular toxicity (CTR-CVT) able to provoke a wide spectrum...

M. Camilli, M. Ortenzi, L. Leo et al. · 0 citations
Open access Aug 2026

InflaMix Predicts Severe CRS, ICU Admission, and Progression‐Free Survival After CAR‐T Therapy in LBCL

The prognostic performance of the recently developed INFLAmmation MIXture Model (InflaMix) in an independent bicentric cohort of patients with large B‐cell lymphoma receiving commercial CAR‐T cells is evaluated, focusing on treatment‐related toxicities.

Eugenio Galli, D. Mannina, Alessandro Corrente et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.